Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14826526 | 0.80 | MMP2 (0.44) | — | |
| SCHEMBL25023217 | 0.80 | MMP2 (0.44) | — | |
| SCHEMBL3830274 | 0.77 | KMT2A (0.31) | KMT2A | |
| SCHEMBL288354 | 0.74 | P2RX7 (0.45) | TSHRACEP2RX7 | |
| SCHEMBL14750046 | 0.74 | P2RX7 (0.45) | TSHRACEP2RX7 | |
| SCHEMBL10137597 | 0.74 | MMP2 (0.40) | TSHRACE | |
| SCHEMBL13688455 | 0.74 | MMP2 (0.40) | TSHRACE | |
| SCHEMBL7265419 | 0.74 | P2RX7 (0.45) | TSHRACEP2RX7 | |
| SCHEMBL12059178 | 0.71 | — | — | |
| SCHEMBL24707475 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044769-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119497712-A | Indane derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20150183763-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8846746-B2 | Pyrazole compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20130085132-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | TSHR 2282/4885ACE 119/4885KMT2A 4152/4885 |
| US-20130085132-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC34A1 | TSHR 2374/4885ACE 298/4885KMT2A 2766/4885 |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | CBR1, CBR3, CNR1 | TSHR 450/4885ACE 1723/4885KMT2A 3299/4885 |
| US-20150183763-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC34A1 | TSHR 2374/4885ACE 298/4885KMT2A 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.